Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis

Published on Jan 1, 2020in EClinicalMedicine
· DOI :10.1016/J.ECLINM.2019.12.007
Michael J. Zoratti2
Estimated H-index: 2
(McMaster University),
Ayesha Siddiqua3
Estimated H-index: 3
(McMaster University)
+ 5 AuthorsEric Druyts20
Estimated H-index: 20
Abstract Background Recent approval and adoption of pangenotypic direct acting antivirals (DAAs) necessitated a revision of the 2015 World Health Organization guidelines for the management of persons with hepatitis C virus (HCV) infection. Methods We searched MEDLINE, EMBASE, CENTRAL, and relevant conference proceedings to identify randomized and non-randomized trials, as well as prospective observational studies of DAAs. The proportions of persons with events were pooled for sustained virological response at 12 weeks post-treatment (SVR12), discontinuations due to adverse events (DAEs), serious adverse events (SAEs), and all-cause mortality. Analyses were stratified by HCV genotype and antiviral treatment experience, with subgroup analyses based on presence of cirrhosis and HIV-HCV coinfection. Findings The evidence base consisted of 238 publications describing 142 studies. In the overall analysis, which included all persons irrespective of treatment experience or comorbidities, the pooled proportion achieving SVR12 exceeded 0.94 for all pangenotypic regimens across genotypes 1, 2, and 4. Some heterogeneity may have led to lower SVR rates in persons with genotype 3 infection. High SVR12 (>0.90) was observed in persons with genotype 1 infection with cirrhosis, though evidence varied and was limited for genotypes 2–4. Evidence was sparse for persons with HIV–HCV coinfection. All regimens were associated with small proportions of persons with DAEs, SAEs, or all-cause mortality. Interpretation Based on this and other supporting evidence, the WHO issued updated guidelines with a conditional recommendation, based on moderate quality evidence, for the use of pangenotypic DAA regimens for persons with chronic HCV infection aged 18 years and older (July 2018). Funding This study was funded by the World Health Organization .
  • References (115)
  • Citations (1)
📖 Papers frequently viewed together
20132.78PLOS ONE
7 Authors (Anna Davies, ..., Nathan Ford)
21 Citations
1 Citations
6 Authors (Cameron Sikavi, ..., Sammy Saab)
9 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Alastair Heffernan (Imperial College London)H-Index: 3
#2Graham S. Cooke (St Mary's Hospital)H-Index: 36
Last. Timothy B. Hallett (Imperial College London)H-Index: 46
view all 5 authors...
Summary Background The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030. We evaluated the impact of public health interventions on the global HCV epidemic and investigated whether WHO's elimination targets could be met. Methods We developed a dynamic transmission model of ...
12 CitationsSource
#1Edward R. Cachay (UCSD: University of California, San Diego)H-Index: 16
#2Álvaro MenaH-Index: 8
Last. W. C. Mathews (UCSD: University of California, San Diego)H-Index: 10
view all 14 authors...
Brazil’s Fight against Hepatitis C Brazil’s strategy for addressing hepatitis C, which combines evidence-based treatment protocols and innovative initiatives for local production of generic direct-...
3 CitationsSource
Universal Access through Lump-Sum Remuneration Australia’s agreement to spend about 1 billion Australian dollars (U.S.$766 million) over 5 years in exchange for an unlimited volume of hepatitis C d...
6 CitationsSource
#1Stefan Wiktor (UW: University of Washington)H-Index: 12
#2Alessio AghemoH-Index: 29
Last. Christophe SarrazinH-Index: 1
view all 6 authors...
Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of...
1,009 CitationsSource
1 CitationsSource
#1Toyoda HidenoriH-Index: 42
#2Kazuaki Chayama (Hiroshima University)H-Index: 89
Last. Hiromitsu KumadaH-Index: 67
view all 22 authors...
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once-daily, all oral, ribavirin (RBV)-free, direct-acting antiviral regimen, was evaluated for safety and efficacy in hepatitis C virus genotype 2 (GT2)–infected Japanese patients, including those with compensated cirrhosis. CERTAIN-2 is a phase 3, open-label, multicenter study assessing the safety and efficacy of G/P (300/120 mg) once daily in treatment-naive a...
32 CitationsSource
#1Giuseppe IndolfiH-Index: 15
15 Citations
#1Marcello Persico (UNISA: University of Salerno)H-Index: 33
#2Andrea Aglitti (UNISA: University of Salerno)H-Index: 5
Last. Mario Masarone (UNISA: University of Salerno)H-Index: 16
view all 9 authors...
The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughout the world. The new interferon-free direct antiviral agents (DAAs) showed high efficacy and safety, and preliminary data seem to confirm their activity on low-grade NHL. The question arises as whether or not—and how—to treat the HCV-positive patients suffering from diffuse large B-cell lymphomas (DLBCLs). The aim of this observational study was to evaluate whether DAA antiviral treatment ...
24 CitationsSource
Cited By1
#1Mary A. RodgersH-Index: 7
Last. Gavin ClohertyH-Index: 12
view all 8 authors...
Although the prevalences of HIV and HCV are significantly higher amongst PWID in India compared to the general population, the strains circulating within this group have not been well-characterized. Through subgenomic sequencing of viruses present in residual plasma from an HIV/HCV prevalence study conducted amongst PWID across five cities in India in 2016–2017, a total of N = 498 HCV and N = 755 HIV strains were classified from N = 975 study participants. Considerable HCV diversity was identifi...